{"id":"W3109003874","doi":"10.1016/j.annonc.2020.10.063","title":"43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Gemcitabine; Internal medicine; Carboplatin; Oncology; Taxane; Triple-negative breast cancer; Progression-free survival; Breast cancer; Population; Pembrolizumab; Metastatic breast cancer; Chemotherapy; Cancer; Cisplatin; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001015573,0.001045571,0.001509262,0.0002453999,0.0003064493,0.0008978953,0.0006212457,0.001013595,0.005383319],"category_scores_gemma":[0.0005642561,0.0004347026,0.001638428,0.0002811095,0.0005700578,0.0005869925,0.0003538273,0.00256863,0.001064052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006155713,"about_ca_system_score_gemma":0.001078135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001347089,"about_ca_topic_score_gemma":0.003461883,"domain_scores_codex":[0.9997551,0.0001116227,0.000009923281,0.0000416041,0.00001819883,0.0000635641],"domain_scores_gemma":[0.999668,0.00005811042,0.00006433826,0.00002417466,0.00001785441,0.0001674374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.906639,0.01574274,0.003496741,0.0008138657,0.001755427,0.00008634393,0.0001376303,0.0009801761,0.01749014,0.0002635156,0.002903712,0.04969084],"study_design_scores_gemma":[0.7627237,0.2146526,0.01450912,0.00006734337,0.001435694,0.0001252373,0.00008902255,0.0006186719,0.0017824,0.0002862747,0.003683355,0.00002660247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878499,0.003363369,0.0005694691,0.0006623832,0.0002516166,0.00150731,0.002310447,0.0001105333,0.003374855],"genre_scores_gemma":[0.9827079,0.002903641,0.001762395,0.001833902,0.0002130765,0.00174216,0.003344737,0.00004324097,0.00544891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005383319,"threshold_uncertainty_score":0.01800895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07946991080433974,"score_gpt":0.405684776383466,"score_spread":0.3262148655791263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}